🇺🇸 FDA
Patent

US 10144726

Modulators of the p70S6 kinase for use in the treatment of brain disorders and triple-negative breast cancer

granted A61KA61K31/498A61K31/53

Quick answer

US patent 10144726 (Modulators of the p70S6 kinase for use in the treatment of brain disorders and triple-negative breast cancer) held by SENTINEL ONCOLOGY LIMITED expires Mon Nov 29 2038 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
SENTINEL ONCOLOGY LIMITED
Grant date
Tue Dec 04 2018 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Nov 29 2038 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
20
CPC classes
A61K, A61K31/498, A61K31/53, A61P, A61P35/04